Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use BESPONSA™ safely and effectively. See full prescribing information for BESPONSA. BESPONSA (inotuzumab ozogamicin) for injection, for intravenous useInitial U.S. Approval: 2017
Medication labelWhy this: Advisory · dailymed-prescription
BESPONSA is indicated for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older.
- generic_name
- inotuzumab ozogamicin
- product_names
- inotuzumab ozogamicin
- ndc
- 0008-0100, 0008-0100-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en